Zacks Investment Research Downgrades 4D Molecular Therapeutics (NASDAQ:FDMT) to Sell

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses […]

Related Keywords

California ,United States ,Emeryville ,Canada ,Zurcher Kantonalbank Zurich Cantonalbank ,D Molecular Therapeutics Company Profile Get Rating ,Zacks Investment Research ,Ensign Peak Advisors Inc ,D Molecular Therapeutics Inc ,Macquarie Group Ltd ,Royal Bank ,Molecular Therapeutics ,Get Rating ,Kantonalbank Zurich Cantonalbank ,Peak Advisors Inc ,Molecular Therapeutics Company Profile ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Downgrade ,